中间葡萄膜炎患者白内障风险研究
基于美国5家三级葡萄膜炎中心的回顾性队列研究,纳入2190眼中间葡萄膜炎,发现白内障1年累积发生率7.6%、10年升至36.6%。并发前葡萄膜炎致后粘连、视网膜前膜及较高剂量糖皮质激素与风险升高相关,低剂量激素未增加风险。
要点
- 中间葡萄膜炎10年白内障累积发生率为36.6%。
- 并发前葡萄膜炎致后粘连者白内障风险显著升高。
- 高剂量糖皮质激素与白内障风险升高相关,低剂量未增加风险。
核心结论
- 中间葡萄膜炎临床重要白内障发生率中等,10年累积达36.6%。
- 疾病严重标志和较高剂量糖皮质激素与白内障风险升高相关,后者可能可调整。
研究设计与样本
- 回顾性队列研究,数据来自系统性免疫抑制治疗眼病队列研究。
- 纳入美国5家三级葡萄膜炎中心1302例患者共2190眼。
- 主要结局为视力下降至20/40或以下或需白内障手术的视力损害性白内障。
主要发现
- 白内障1年累积发生率为7.6%(95%CI=6.2%-9.1%),10年升至36.6%(95%CI=31.2%-41.6%)。
- 并发前葡萄膜炎致后粘连者白内障风险升高(HR=2.68,95%CI=2.00-3.59,P<.001)。
- 视网膜前膜形成者白内障风险升高(HR=1.54,95%CI=1.15-2.07,P=.004)。
- 较高剂量糖皮质激素治疗与白内障发生率显著升高相关,尤其是时间更新使用局部激素≥2次/天或≥4次眼周注射。
- 低剂量糖皮质激素(口服泼尼松≤7.5 mg/天或局部激素滴眼<2次/天)未与白内障风险升高相关。
关键数值与推荐
- 视力损害性白内障定义为视力下降至20/40或以下或需白内障手术。
- 并发前葡萄膜炎致后粘连的HR=2.68(95%CI=2.00-3.59,P<.001)。
- 视网膜前膜的HR=1.54(95%CI=1.15-2.07,P=.004)。
- 高剂量激素:局部激素≥2次/天或眼周注射≥4次与风险升高相关。
- 低剂量激素:口服泼尼松≤7.5 mg/天或局部激素<2次/天未增加风险。
临床怎么用
- 中间葡萄膜炎患者应监测白内障,尤其病程长或合并前葡萄膜炎、视网膜前膜者。
- 治疗中尽量采用低剂量糖皮质激素以降低白内障风险。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To determine the incidence of and predictive factors for cataract in intermediate uveitis. DESIGN: Retrospective cohort study. METHODS: Patients were identified from the Systemic Immunosuppressive Therapy for Eye Diseases Cohort Study, in which medical records were reviewed to determine demographic and clinical data of every eye/patient at every visit at 5 participating US tertiary care uveitis centers. The primary outcome was development of vision-compromising cataract as defined by a decrease in visual acuity to 20/40 or less, or requiring cataract surgery. Survival analysis assessed visually defined cataract to avoid bias due to timing of surgery vis-à-vis inflammatory status. RESULTS: Among 2,190 eyes of 1,302 patients with intermediate uveitis, the cumulative incidence of cataract formation was 7.6% by 1 year (95% confidence interval [CI] = 6.2%-9.1%), increasing to 36.6% by 10 years (95% CI = 31.2%-41.6%). Increased cataract risk was observed in eyes with concurrent anterior uveitis causing posterior synechiae (hazard ratio = 2.68, 95% CI = 2.00-3.59, P < .001), and in eyes with epiretinal membrane formation (hazard ratio = 1.54, 95% CI = 1.15-2.07, P = .004). Higher dose corticosteroid therapy was associated with significantly higher incidence of cataract, especially time-updated use of topical corticosteroids ≥2 times/d or ≥4 periocular corticosteroid injections. Low-dose corticosteroid medications (oral prednisone 7.5 mg daily or less, or topical corticosteroid drops <2 times/d) were not associated with increased cataract risk. CONCLUSIONS: Our study found that the incidence of clinically important cataract in intermediate uveitis is moderate. The risk is higher with markers of severity and with higher doses of corticosteroid medications, the latter being potentially modifiable.
引用
- Minkus CL, Pistilli M, Dreger KA, et al. Risk of Cataract in Intermediate Uveitis. Am J Ophthalmol. 2021. PMID: 33713679. doi:10.1016/j.ajo.2021.02.032
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。